
In vitro Nano-Check™ AMI 3 IN 1 Cardiac Marker Test

cTnI, CK-MB, and Myoglobin

One Step Test Strip for AMI Test

For in vitro Diagnostic Use

One-step qualitative and quantitative immuno-chromatographic assay for the detection of cTnI, CK-MB, and Myoglobin in human whole blood, serum, and plasma

Cat No. ND-CD302P
Manufactured for CLIAwaived, Inc

1. INTENDED USE

The Nano-Check™ AMI 3 IN 1 Test is a rapid immunoassay for the qualitative and quantitative determination of Cardiac Troponin I (cTnI), Creatine Kinase MB (CK-MB), and Myoglobin in human whole blood, serum and plasma specimens at cutoff concentrations of 0.5 ng/ml, 5.0 ng/ml, and 80 ng/ml respectively, as an aid in the diagnosis of Acute Myocardial Infarction (AMI). In conjunction with Nano-Checker 710 reader, the Nano-Check™ AMI 3 IN 1 Test can monitor the rise and fall of cTnI, CK-MB, and Myoglobin. Test results should be interpreted by the physician along with other test results and patient clinical symptoms findings.

2. SUMMARY AND EXPLANATION OF THE TEST

When a myocardial infarction (MI) occurs in the hypoperfused region of the myocardium, oxygen can no longer be supplied to the cells in the region. Cell death is inevitable if oxygen is not restored within 10-15 min. Cell death results in the release of certain proteins from within cytoplasm into the blood stream. Some proteins are exclusive to and predominant in the cardiac muscle cells; they can function as cardiac makers and be detected in the blood specimens of AMI patients by specialized immunoassays.¹⁻³ Unfortunately none of cardiac markers that have been discovered show early release, have 100% cardiac specificity, and a substantial life time in circulation. This situation has led to a panel approach for the utilization of markers in patients with AMI. The constituents of this cardiac panel should include a marker that rapidly increases after cardiac injury and is highly cardiac tissue specific. The combination of cTnI, CK-MB and Myoglobin are widely used in panel assays intended for the determination of AMI in chest pain patients.⁴

Troponin I

Troponin is a contractile regulatory protein complex found in skeletal and cardiac muscle. The Troponin complex consists of three distinctive polypeptide components, troponin I (TnI), troponin T (TnT), and troponin C (TnC), and plays a fundamental role in the transmission of intracellular calcium signal actin-myosin interaction.⁵ TnC of cardiac tissues is identical to that in skeletal tissues, but TnI and TnT of cardiac isoforms are distinctive to those of skeletal isoforms, which enables the development of cardiac specific antibodies.⁶ Moreover, cTnI level becomes elevated in the blood as a result of myocardial injury or necrosis. Therefore, cTnI is used as an aid in the diagnosis of myocardial infarction.⁷⁻⁸ Studies on the release kinetics indicate that cTnI is not early marker of myocardial necrosis. It appears in serum within 3-6 hours after symptom onset, similar to the release of CK-MB. However, cTnI remains elevated for 4-9 days post-AMI.⁹⁻¹⁰ In addition to its utility in diagnosis, elevated troponin I levels convey prognostic information and has been shown to identify patients having an increased risk of death.¹¹

CK-MB

Creatine Kinase (CK) is present in most tissues and is primarily concerned with ATP regeneration. This enzyme is dimeric and exists as three isozymes: MM (muscle), MB (hybrid), and BB (brain).¹² The MB isozyme has its highest concentration in the heart muscle, thus its level in the serum has diagnostic value. The CK-MB level in normal serum is less than 5 ng/ml. In cases of uncomplicated AMI, CK-MB level becomes elevated within 4-8 hours after the onset of chest pain, reaching a peak between 12-24 hours and then drops down to normal by 48 hours. The peak level of CK-MB is 21 ng/ml or higher.¹³⁻¹⁴ CK-MB has been considered the gold standard for the diagnosis of AMI because of its cardio-specificity. However, CK-MB is not an ideal marker to use alone because its level does not increase early enough to make a rapid diagnosis and may also be increased in other conditions. Although CK-MB is more concentrated in the myocardium (approximately 15% of the total CK), it is also present in skeletal muscle. False-positive elevations occur in a number of clinical settings, including trauma, heavy exertion, and myopathies.¹⁵⁻¹⁶

Myoglobin

Myoglobin, an oxygen binding heme protein present in muscle tissue including cardiac, skeletal and smooth muscle, has attracted considerable interest as an early marker of MI.^{2,17} Following injury to any of these muscles, myoglobin appears in the blood more rapidly than any other marker⁴. Levels may be elevated as early as one hour following the onset of chest pain when CK-MB levels are still in the range of normal.^{2,18,19} This rapid appearance is due to the location of myoglobin in the cell and its low molecular weight. Myoglobin typically rises 2-4 hours after the onset of infarction, peaks at 6-12 hours, and returns to normal within 24-36 hours. Normally the level of myoglobin in serum is 30-80 ng/ml. In patients with MI, the level could increase approximately 10 times above the upper limit of normal. Myoglobin exhibits high clinical sensitivity for AMI but poor specificity.^{1,3} Many studies suggest that myoglobin may be a good screening assay in Emergency Rooms for the early diagnosis of AMI. However, elevated myoglobin values should be cautiously interpreted if the patient has renal dysfunction or skeletal muscle injury. Because of these limitations, detection of myoglobin in a patient suspected of AMI may need to be supplemented by the presence of a more definitive cardiac maker. However, a negative result in a patient admitted within 2-9 hours after onset of chest pain may help in ruling out AMI.

3. PRINCIPLE

The Nano-Check™ AMI 3 IN 1 Test is an immunochromatography assay for the qualitative and quantitative determination of three biochemical markers (cTnI, CK-MB and Myoglobin) simultaneously in human whole blood, serum and plasma specimen. The membrane strip contains three test lines and one control line, printed with specific antibodies or receptor against each target molecules, monoclonal mouse antibody against CK-MB, monoclonal mouse antibody against Myoglobin, streptavidin for biotinylated cTnI antibody, and rabbit anti-goat antibody for control line. A dye pad is placed at the end of the membrane containing biotinylated cTnI antibody and gold colloidal particles coupled with CK-MM, cTnI and Myoglobin antibodies. When a sample is applied into the sample well, the cardiac makers present in the sample bind to the specific antibodies coupled with gold particles on the dried dye pad. cTnI in a sample binds to both cTnI specific dye coupled antibody and biotinylated antibody. These primary immune complexes move along the nitrocellulose membrane through the test lines and bind to their corresponding capture antibodies or receptor molecules immobilized on the test line. Unbound immune complexes pass through the test line and are captured by goat anti mouse antibody in the control line.

If the concentration of any of these three markers in the sample is above the cutoff level, red bands appear at the corresponding test lines and the control line. If the concentration of the markers in the sample is lower than the cutoff level, only the colored control line can be seen in the test window. This colored control band must always appear at the control line position (Con) for valid test results. A test result is not valid if the colored control line does not appear in the test window.

To measure the concentration of analyte, the tested device should be read by Nano-Checkre710 reader. The reader can analyze color intensity of the test line and convert it to concentration of the analyte in the specimen by the predetermined equation. .

4. REAGENT

The Nano-Check™ AMI 3 IN 1 Test contains all the reagents necessary for the detection of cTnI, CK-MB and Myoglobin in human whole blood, serum, and plasma. The device contains a membrane strip coated with monoclonal mouse anti-CK-MB, anti- Myoglobin and streptavidin on the test line, and dye pad infused with biotinylated monoclonal mouse anti-cTnI antibody and gold colloidal particles coupled with anti-CK-MM, anti-cTnI and anti-Myoglobin antibodies. Stabilizer containing 0.05% sodium azide and BSA protein are deposited on the dye pad in dried form.

5. MATERIALS

Provided

- Nano-Check™ 3 IN 1 Test device containing membrane strip in a sealed pouch with desiccant
- Instructions for Use
- Disposable pipette (if applicable)

Required but not provided

- Whole blood, Serum or Plasma Collection Container
- Positive and negative quality control materials
- Timer
- Nano-Checker 710 or equivalent Nano-Checker Reader (For quantitative analysis)

6. STORAGE AND STABILITY

The test kit should be stored at 4°C - 30°C in the original sealed pouch for the duration of shelf life.

7. PRECAUTIONS

- For in-vitro diagnostic and professional use only.
- Handle all specimens as potentially infectious. Proper handling and disposal methods should be established.
- To avoid cross contamination, use a fresh transfer device for each clinical sample tested.
- Do not use test kit if the pouch is damaged or improperly sealed.
- Do not use test kit beyond expiration date.

8. SPECIMEN COLLECTION AND PREPARATION

- This test can be used for whole blood, plasma, and serum samples. If serum samples are to be used, collect the blood in a tube without anticoagulant and allow clotting for at least 25 minutes before centrifugation. Whole blood or plasma samples using heparin or EDTA as the anticoagulant can be used for testing with this product. Other blood anticoagulants have not been evaluated. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variation in these products may exist between manufacturers and, at times, from lot-to-lot.
- The samples should be collected under standard laboratory conditions.
- Optimal results were obtained when patient samples were tested immediately after collection. Whole blood samples should be used within 4 hours after collection. Plasma or serum samples may be refrigerated for 24 hours at 2-8°C. If testing cannot be performed within 24 hours, or for shipment of samples, freeze at -20°C or colder.^{20, 21}
- Sodium azide can be added as a preservative up to 0.1% without affecting the test results.
- Refrigerated or frozen serum or plasma specimen should reach room temperature and be homogeneous prior to testing

9. TEST PROCEDURE AND PROTOCOL

1. Collect specimen according to instructions in “Specimen Collection”.
2. Test device and sample should be brought to room temperature (20°C-30°C) prior to testing. Do not open pouches until ready to perform the assay.
3. Remove the test device from the sealed pouch immediately before use. Label the device with patient or control identification.
4. Using sample transfer pipette, deliver dropper contents (80 µl) of sample into the sample well.
5. Read the results at 15 minutes. For qualitative interpretation of results, please see section below, “Interpretation of Results”. Do not interpret results after 15 minutes. For the quantitative result, the tested device should be analyzed by the Nano-Checker 710 reader following by the instruction manual.

10. INTERPRETATION OF RESULTS

Qualitative Analysis

The results of the Nano-Check™ Cardiac 3 IN 1 Test are determined visually and interpreted according to the predetermined cutoff values of 0.5 ng/ml for cTnI, 5 ng/ml for CK-MB and 80 ng/ml for Myoglobin. These cutoff levels were determined by comparison to the quantitative assay system of Beckman Coulter, Access AccuTnI™, Access CK-MB Assay and Access Myoglobin Assay. These cutoff levels may be different if compared to a quantitative assay system other than Beckman Coulter. We recommend that users should establish a correlation if a quantitative assay system other than Beckman Coulter Access is used.

Negative: A single red colored band at the control area (Con) without any other bands at test lines (TnI, CK-MB, Myo) is a valid negative result and indicates the concentrations of cTnI, CK-MB and Myoglobin in the sample are below the cutoff levels.

Positive: Appearance of red colored band at the control area (Con) and appearance of red colored bands in any of test lines indicate that concentrations of cTnI, CK-MB, and/or Myoglobin in the sample, which are shown as the colored band, are at or above the cutoff levels. The intensity of red color in the test line may be weaker or stronger than that in the control line.

Invalid: If no colored band appears in the control area in 15 minutes (Con), the test result is invalid. The test result is inconclusive and the assay should be repeated.

Note:

- Very faint bands in the test lines indicate that the proteins in the specimen are near the cutoff level of the test. These samples should be re-tested 1-2 hours later or test results should be confirmed by quantitative assay.
- Do not interpret the results after 15 min.

	VALID				INVALID		
Con							
TnI							
CK-MB							
Myo							
TnI	-	-	-	+	Any result without control line		
CK-MB	-	-	+	+			
Myo	-	+	+	+			

Quantitative Analysis

The signal intensity of test line can be analyzed by Nano-Checker 710 reader and reported as concentration of analyte in the tested specimen. When the test result is valid and measured value is in the range of reference value, the result can be interpreted as a negative of AMI. The value is above the reference range but below cutoff value, the specimen should be retested after an hour. The reading value is above the cutoff value, the result can be interpreted as a positive.

11. LIMITATIONS

- The test is for professional and *in-vitro* diagnostic use only.
- A positive test result may only be used as an indicator of myocardial damage and requires further confirmation. Serial sampling of patients suspected of AMI at multiple time points is also recommended due to the delay between onset of symptoms and the release of cardiac marker proteins into the blood stream.
- As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the results of a single test. The test result should be used in conjunction with other clinical information such as clinical signs and symptoms and other test results to diagnose AMI. Confirmation of test results should only be made by a physician after all clinical and laboratory findings have been evaluated.
- Samples containing unusually high titers of certain antibodies such as human anti-mouse or human anti-rabbit antibodies have been known to affect the performance of these devices.²² However these studies using the Nano-Check AMI 3IN 1 Test have not been performed.

12. QUALITY CONTROL

The presence of a reddish colored band in the Control area of the window acts as an internal control to ensure that an adequate volume of sample has been added. In the absence of this Control band, the test is invalid and must be repeated. Good laboratory practice recommends the use of control materials to ensure proper kit performance. Quality control specimens are available from commercial sources, and should be assayed using the same procedures followed when running patient samples. Controls should minimally be run before using each new lot or shipment of Nano-Check™ AMI 3 IN 1 Test, at regular intervals afterwards and any time the validity of the test results are questioned. For the calibration of Nano-Checker 710 reader, two different levels of calibration cards are supplied with the reader. The reader should be calibrated periodically with the provided calibration card. If the reading value of calibration card is out of the described range, it should be recalibrated.

13. EXPECTED VALUES

The cutoff values of the Nano-Check™ AMI 3 IN 1 Test were determined by comparison to the Beckman Coulter quantitative assay, Access AccuTnI™, Access Myoglobin Assay, or Access CK-MB Assay. The cutoff level of each cardiac maker is 0.5 ng/ml for cTnI, 5 ng/ml for CK-MB and 80 ng/ml for Myoglobin. The specimens containing cTnI, CK-MB and Myoglobin, at the concentration of equal or above established cutoff levels will give positive results using the Nano-Check™ AMI 3 IN 1 Test. The cutoff levels may be different if a quantitative assay system other than Beckman Coulter Access is used.

14. PERFORMANCE CHARACTERISTICS

1. Assay Cutoff

Patient serum containing cTnI, CK-MB or Myoglobin were diluted in normal human serum to the concentration at or near the cutoff levels. Analyte concentrations in the diluted samples were confirmed by Quantitative Assay, Access AccuTnI™, Access Myoglobin Assay, or Access CK-MB Assay of Beckman Coulter. Fifteen devices were tested for each samples at concentrations of 0.31, 0.57 and 1.07 ng/ml for cTnI; 2.4, 4.9, and 10.2 ng/ml for CM-MB; 56.5, 80.4 and 141.3 ng/ml for Myoglobin. The results are shown in following table. The cutoff concentrations were assigned as 0.5 ng/ml for cTnI, 5.0 ng/ml for CK-MB and 80 ng/ml for Myoglobin.

Analyte	Conc. determined by Access Assay (ng/ml)	Test Result		Cutoff level
		Negative (n)	Positive (n)	
cTnI	0.31	7	8	0.5 ng/ml
	0.57	0	15	
	1.07	0	15	
CK-MB	2.4	15	0	5.0 ng/ml
	4.9	0	15	
	10.2	0	15	
Myoglobin	56.5	14	1	80 ng/ml
	80.4	0	15	
	141.3	0	15	

2. Recovery Studies

Recovery studies were performed with patient serum diluted in normal human serum. Patient sera containing high levels of either cTnI, CK-MB or Myoglobin were sequentially diluted with normal human serum to yield different concentrations. Each diluted sample was tested using Nano-Check™ AMI 3 IN 1 Test in 3 replicates. The data shown in the table below demonstrates recovery rate between observed results and expected results at each concentration of cTnI, CK-MB and Myoglobin.

Analyte	Expected Concentration(ng/ml)	Determined Average Concentration	Agreement % of Expected values	Total Recovery (%)
cTnI	44.8	41.13	91.8	104.2
	22.4	24.17	107.8	
	11.2	10.17	90.8	
	5.6	5.00	89.3	
	2.8	3.60	128.6	
	1.4	1.87	133.3	
	0.7	0.80	114.3	
	0.35	0.37	105.6	
	0.18	0.13	76.2	
CK-MB	188	199.7	106.2	100.7
	94	101.3	107.8	
	47	42.1	89.6	
	23.5	26.6	113.0	
	11.8	12.5	106.4	
	5.9	7.7	130.5	
	2.9	3.3	113.5	
	1.5	0.6	38.6	
Myoglobin	1074	1069.7	99.6	101.2
	716	643.0	89.8	
	358	343.7	96.0	
	179	174.4	97.4	
	89.5	90.8	101.4	
	44.8	61.4	137.2	
	22.4	19.4	86.9	

3. Analytical Specificity

Potentially interfering substances were spiked into normal serum and patient serum containing either cTnI, CK-MB or Myoglobin, about 1.5 times of the cutoff concentration. The substances at the following level do not interfere with the performance of the Nano-Check™ AMI 3 IN 1 Test.

	Substances	Concentration
Endogenous substances	Bilirubin	50 mg/dl
	Hemoglobin	4000 mg/dl
	Human serum albumin	10g /dl
	Triglycerides	1,250 mg/dl

The device was tested for interference by potentially cross-reacting endogenous proteins. Potentially cross-reacting proteins, added into normal human serum up to the following concentrations, do not interfere with test result.

	Substances	Concentration
Cross-reacting endogenous proteins	Cardiac myosin light chain	1,000 ng/ml
	Cardiac Troponin T	1,000 ng/ml
	Cardiac Troponin C	1,000 ng/ml
	Skeletal Troponin I	1,000 ng/ml
	CKMM	5,000 ng/ml

4. Precision Test

Two Clinical sites and one in-house operator were provided with blindly labeled serum samples. Patient serum samples, containing high levels of cTnI, CK-MB and Myoglobin, were diluted in normal human serum to make positive samples of different concentrations. A normal human serum sample was also provided as negative control of the test. Five aliquots from each sample were tested at each testing site. The results shown in the table below demonstrate 100% agreement for between run as well as for within run.

Analyte	Testing Site	Concentration of each analyte (ng/ml) in each sample and Nano-Check™ AMI 3 IN 1 Test Precision Testing Result						% agreement within run
		Sample 1		Sample 2		Sample 3		
		cTnI	0	cTnI	1.03	cTnI	2.05	
		CK-MB	0	CK-MB	12.6	CK-MB	25.0	
		Myo	0	Myo	119.9	Myo	166.3	
		-	+	-	+	-	+	
cTnI	Site 1	5	0	0	5	0	5	100%
	Site 2	5	0	0	5	0	5	100%
	Site 3	5	0	0	5	0	5	100%
	% agreement between run	100%		100%		100%		
CK-MB	Site 1	5	0	0	5	0	5	100%
	Site 2	5	0	0	5	0	5	100%
	Site 3	5	0	0	5	0	5	100%
	% agreement between run	100%		100%		100%		
Myo	Site 1	5	0	0	5	0	5	100%
	Site 2	5	0	0	5	0	5	100%
	Site 3	5	0	0	5	0	5	100%
	% agreement between run	100%		100%		100%		

5. Reproducibility test for Nano-Check AMI 3 in 1 Quantitative Assay

Reproducibility of the Nano-Check AMI 3 in 1 quantitative assay system with Nano-Checker 710 reader was determined in a study using plasma based in-house control materials. Specimens at each level were tested in duplicate for 10 days. The within run and total standard deviation were calculated by the analysis of variance method.

Analyte	Samples	Mean (ng/ml)	SD within- run	Total CV (%)
<i>cTnI</i>	Level 1	0.66	0.15	22.85
	Level 2	2.54	0.32	12.76
	Level 3	18.21	2.31	12.67
<i>CK-MB</i>	Level 1	8.74	1.57	17.99
	Level 2	42.57	4.96	11.66
	Level 3	177.07	27.07	15.29
<i>Myoglobin</i>	Level 1	83.5	13.64	16.33
	Level 2	252.77	35.56	14.07
	Level 3	843.54	153.83	18.24

6. Correlation Assay between Plasma and Serum Sample

Patient samples were prepared for matched samples of serum and heparinized plasma. Samples were grouped as four different levels; 1.2-1.8, 0.5-1.0, 0.3-0.5 and <0.06 ng/ml for cTnI; 11-20, 5-10, 3.8-4.4 and <2 ng/ml for CK-MB; 123-248, 85-118, 64-80 and <30 ng/ml for Myoglobin. Ten samples in each group were tested using Nano-Check™ AMI 3 in 1 Test, and the results demonstrated in the following table:

Analyte	Concentration range of samples (ng/ml)	Serum Positive	Serum Negative	Plasma Positive	Plasma Negative
TnI	1.2-1.8	10	0	10	0
	0.5-1.0	10	0	10	0
	0.3-0.5	9	1	7	3
CK-MB	11-20	10	0	10	0
	5-10	10	0	10	0
	3.8-4.4	8	2	7	3
Myo	123-248	10	0	10	0
	85-118	10	0	10	0
	64-80	8	2	9	1

7. Correlation Assay between Whole blood and Plasma Sample.

To test correlation of assay results between plasma and whole blood samples in Nano-Check™ AMI 3 IN 1 qualitative test, normal whole blood samples were spiked with clinical specimens containing each analyte, cTnI, CK-MB, Myoglobin to make three different desired levels between negative and 4 times then cut off values of each analyte. Five samples in each group were tested using Nano-Check™ AMI 3 IN 1 Test, prior to removal of cells and after removal of cells by centrifugation. The test results are demonstrated in the following table:

Analyte	Concentration range of samples (ng/ml)	Plasma Positive	Plasma Negative	Whole Blood Positive	Whole Blood Negative
TnI	1.3-2.4	5	0	5	0
	0.5-1.0	5	0	5	0
	0.1-0.47	3	2	2	3
CK-MB	11.4-15.6	5	0	5	0

	5.0-10.0	5	0	5	0
	2.2-4.6	1	4	1	4
Myo	151-211	5	0	5	0
	83.6-138	5	0	5	0
	63.0-81.5	1	4	1	4

8. Matrix Comparison Study in Quantitative Assay

To perform matrix comparison study between plasma and whole blood in Nano-Check™ AMI 3 IN 1 quantitative test, ten different levels of analyte concentrations ranging from negative to upper detection limit were prepared by spiking analyte molecules into normal whole blood collected from 8 different healthy volunteers. Corresponding plasma specimens were prepared from each level of whole blood specimens by centrifugation. Each level of whole blood and plasma specimens were run on the same lot of Nano-Check AMI 3 in 1 device in 3 replicates. The concentrations were measured using the matrix specific analysis programs for whole blood and plasma test on Nano-Checker 710 reader. From the test result, the following correlations were acquired. The formulas prove that the test values of whole blood were correlated to them of plasma with 83-96% correlation coefficient. The analyte concentrations in plasma were plotted against those in whole blood and the tables show the correlation between two different matrixes. A similar analysis was performed for the correlation in plasma treated with different anticoagulants.

Lithium Heparin Plasma vs. Whole Blood

Analyte	n	Ranges of Observation (ng/ml)	Intercept (ng/ml)	Slope	Correlation Coefficient
Tn I	30	0 -64	0.0321	0.9575	0.951
CK-MB	30	0-256	0.7452	0.9702	0.963
Myoglobin	30	0-1280	25.545	0.9117	0.827

EDTA Plasma vs. Whole Blood

Analyte	n	Ranges of Observation (ng/ml)	Intercept (ng/ml)	Slope	Correlation Coefficient
Tn I	30	0 -64	-0.0436	0.9413	0.936
CK-MB	30	0-256	0.9751	0.9502	0.951
Myoglobin	30	0-1280	21.545	0.8942	0.863

Lithium Heparin Plasma vs. EDTA Plasma

Analyte	n	Ranges of Observation (ng/ml)	Intercept (ng/ml)	Slope	Correlation Coefficient
Tn I	30	0 -64	0.0267	0.9175	0.948
CK-MB	30	0-256	0.5123	0.9502	0.951
Myoglobin	30	0-1280	-16.545	0.9342	0.893

9. Method Comparison Study

i) Qualitative test Comparison.

Plasma samples were collected from 206 emergency room patients who were admitted because examination results suggested a cardiac event. Additionally, 50 samples were collected from outpatients who were not suspected of having a cardiac event. The 256 clinical samples were tested using the Nano-Ditech™ AMI 3 IN 1 Test and the Beckman Coulter Access test system. Results are summarized below.

AMI 3 IN 1 TnI Test Results Compared to Quantitative Access Results (ng/ml)

		Access Accu TnI Test Result			
		0.023-0.29	0.3-0.47	0.52-0.6	0.61->100
Nano-Check™ 3 in1 cTnI	Positive	1	7	6	91
	Negative	143	6	2	0

AMI 3 IN 1 CK-MB Test Results Compared to Quantitative Access Results (ng/ml)

		Access CK-MB Test Result			
		0.7-4.0	4.1-4.9	5.0-6.0	6.2->300
Nano-Check™ 3 in1 CK-MB	Positive	1	9	15	99
	Negative	121	10	1	0

AMI 3 IN 1 Myoglobin Test Results Compared to Quantitative Access Results (ng/ml)

		Access Myoglobin Test Result			
		10.2-60.9	61-79.1	80.4-90.3	91.9->4000
Nano-Check™ 3 in1 Myo	Positive	0	9	11	120
	Negative	98	16	2	0

ii) Quantitative test Comparison

A comparison of Tn I, CK-MB and Myoglobin values of heparin plasma samples with Nano-Check AMI 3in1 assay system using Nano-Checker 710 reader and Beckman Coulter Access system were carried out. The results of cTn I, CK-MB and Myoglobin values obtained by two different methods were analyzed to give the following statistical data.

Analyte	n	Ranges of Observation (ng/ml)	Intercept (ng/ml)	Slope	Correlation Coefficient
Tn I	67	0.06-44.80	0.5348	0.9175	0.948
CK-MB	62	0-188	0.6855	0.9502	0.951
Myoglobin	55	0-1587	85.545	0.7242	0.813

15. REFERENCES

- Panteghini M, Pagani F, Bonetti G. (1999) the sensitivity of cardiac markers: an evidence-based approach. Clin Chem Lab Med. 37(11-12):1097-106
- Wu AH. (1997) Use of cardiac markers as assessed by outcomes analysis. Clin Biochem. 30(4):339-50
- Apple FS. (1992) Acute myocardial infarction and coronary reperfusion. Serum cardiac markers for the 1990s. Am J Clin Pathol. 97(2):217-26
- Alan H.B. Wu, Fred S. Apple, W. Brian Gibler, Robert L. Jesse, Myron M. Warshaw, and Roland Valdes, Jr. (1999) The National Academy of Clinical Biochemistry Laboratory Medicine Practice: Recommendations for the use of cardiac markers in coronary artery diseases. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines
- Mehegan JP, Tobacman LS. (1991) Cooperative interactions between troponin molecules bound to the cardiac thin filament. J Biol Chem. 266(2):966-72
- Bodor GS, Porter S, Landt Y, Ladenson JH (1992) Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem. 38(11):2203-14
- Adams JE 3rd, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS (1993) Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 88(1):101-106
- Adams JE 3rd, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Davila-Roman VG, Bodor GS, Ladenson JH, Jaffe AS (1994) Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med. 330(10):670-674

9. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. (1995) Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. *Clin Chem.* 41(9):1266-72
 10. Mair J, Genser N, Morandell D, Maier J, Mair P, Lechleitner P, Calzolari C, Larue C, Ambach E, Dienstl F, Pau B, Puschendorf B.(1996) Cardiac troponin I in the diagnosis of myocardial injury and infarction. *Clin Chim Acta.* 245(1):19-38
 11. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E.(1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. *N Engl J Med.* 335(18):1342-9
 12. Neumeier D (1981) Tissues specific and subcellular distribution of creatine kinase isoenzymes. In *Creatine Kinase Isoenzymes* (ed, Lang H) Springer Verlag, p85
 13. Lott JA. (1984) Serum enzyme determinations in the diagnosis of acute myocardial infarction: an update. *Hum Pathol.* 15(8):706-16
 14. Gulbis B, Unger P, Lenaers A, Desmet JM, Ooms HA. (1990) Mass concentration of creatine kinase MB isoenzyme and lactate dehydrogenase isoenzyme 1 in diagnosis of perioperative myocardial infarction after coronary bypass surgery. *Clin Chem.* 36(10):1784-8
 15. Ruppert M, Van Hee R. (2001) Creatinine-kinase-MB determination in non-cardiac trauma: its difference with cardiac infarction and its restricted use in trauma situations. *Eur J Emerg Med.* 8(3):177-9
 16. Schneider CM, Dennehy CA, Rodearmel SJ, Hayward JR. (1995) Effects of physical activity on creatine phosphokinase and the isoenzyme creatine kinase-MB. *Ann Emerg Med.* 25(4):520-4
 17. Montague C, Kircher T. (1995) Myoglobin in the early evaluation of acute chest pain. *Am J Clin Pathol.* 104(4):472-6
 18. Carraro P, Plebani M, Varagnolo MC, Zaninotto M, Rossetti M, Burlina A. (1994) A new immunoassay for the measurement of myoglobin in serum. *J Clin Lab Anal.* 8(2):70-5
 19. Clerico A, Emdin M, Del Chicca MG, Carpeggiani C, Zucchelli GC, Boni C, Di Pasquale G, Pinelli G. (1993) Immunoradiometric assay of serum myosin as a marker of myocardial cell damage: methodological and clinical evaluation. *J Nucl Biol Med.* 37(1):33-7
 20. The Clinical and Laboratory Standards Institute (CLSI) (2003) Approved Standard H03-A5; Procedure for the Collection of Diagnostic Blood Specimens by Venipuncture, Fifth Edition.
 21. The Clinical and Laboratory Standards Institute (CLSI) (2004) Approved Guideline H18; Procedures for the Handling and Processing of Blood Specimens, Third Edition.
 22. Kazmierczak, S., Catrou, P., Briley, K. (2000), Transient Nature of Interference Effects from Heterophile Antibodies: Examples of Interference with Cardiac Marker Measurements. *Clin Chem Lab Med;* 38(1):33-9
-